companies / terremoto-bio
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-04-29 json
| total_raised | 250,000,000250.0M | ○ |
|---|---|---|
| founded | null | |
| hq | South San Francisco, USA | |
| industry | unknown | |
| stage | series-b+ |
Terremoto Biosciences develops oral small-molecule drugs using novel covalent chemistry for surgical selectivity against AKT1 in cancer and hereditary hemorrhagic telangiectasia. Its covalency platform unlocks previously undruggable targets, serving patients where earlier AKT inhibitors failed on safety or durability grounds.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2026-04-01 | series-d+ | 108,000,000108.0M | null | ○ |
Cloudflare, All in One SEO 4.9.7.2, All in One SEO Pack 4.9.7.2, Kinsta, Google Analytics, Google Tag Manager, Slick 1.8.1, jQuery Migrate 3.4.1, parallax.js, DoubleClick Floodlight, cdnjs, Cloudflare Bot Management
| fact | status | src |
|---|---|---|
| Series D+, $108.0M | attributed | ○ |
| existence | self-reported | WEB |
| description | self-reported | WEB |